Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996288 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL445610 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL19119024 | 0.75 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1SMN1; SMN2LMNA | |
| SCHEMBL28859209 | 0.74 | CYP1A2 (0.43) | SLC1A3SLC1A2SLC1A1SMN1; SMN2 | |
| SCHEMBL10768520 | 0.73 | — | — | |
| SCHEMBL9843858 | 0.73 | — | — | |
| SCHEMBL447796 | 0.73 | — | — | |
| SCHEMBL15626642 | 0.73 | SLC1A3 (0.44) | SLC1A3SLC1A2SLC1A1FFAR1L3MBTL1 | |
| SCHEMBL2557758 | 0.72 | SMN1; SMN2 (0.38) | SMN1; SMN2CYP4F2CYP4A11 | |
| Bromide SCHEMBL28346228 | 0.72 | PPARA (0.43) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-12-19 | — | — | US | disclosed |
| EP-3630291-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215801-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417388-A1 | BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 | BCL6, BCL6B, BCL3 | SLC1A3 4839/4885SLC1A2 4878/4885SLC1A1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.